Drug Profile
Promethazine/hydrocodone/paracetamol - Charleston Laboratories
Alternative Names: CL-108; HYDEXOR; Hydrocodone/paracetamol/promethazine; Paracetamol/promethazine/hydrocodoneLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Charleston Laboratories
- Class Acetanilides; Aminophenols; Antiallergics; Antiemetics; Antipyretics; Antitussives; Hypnosedatives; Morphinans; Non-opioid analgesics; Opioid analgesics; Opioid peptides; Propylamines; Sedating antihistamines
- Mechanism of Action Histamine H1 receptor antagonists; Muscarinic receptor antagonists; Opioid receptor agonists; Prostaglandin receptor antagonists; Serotonin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Acute pain; Nausea and vomiting
Most Recent Events
- 22 Feb 2023 Phase III development is for Acute pain and Nausea and vomiting is still ongoing USA (Charleston Laboratories pipeline, February 2023)
- 23 Feb 2021 Phase III development is for Nausea and vomiting (Prevention) is still ongoing USA (PO, Tablet, 12.5mg/10mg/325mg) (Charleston Laboratories pipeline, February 2021)
- 23 Feb 2021 Phase III development is for Nausea and vomiting (Prevention) is still ongoing USA (PO, Tablet, 12.5mg/5mg/325mg) (Charleston Laboratories pipeline, February 2021)